145 related articles for article (PubMed ID: 31898103)
1. Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma.
Song Y; Straker RJ; Xu X; Elder DE; Gimotty PA; Huang AC; Mitchell TC; Amaravadi RK; Schuchter LM; Karakousis GC
Ann Surg Oncol; 2020 Aug; 27(8):2915-2926. PubMed ID: 31898103
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
4. Perioperative immune checkpoint blockades improve prognosis of resectable non-small cell lung cancer.
Tian Y; Liu Z; Pan H; Zhu H; Zou N; Jiang L; Li Z; Huang J; Hu Y; Luo Q
Eur J Cardiothorac Surg; 2024 Mar; 65(4):. PubMed ID: 38530978
[TBL] [Abstract][Full Text] [Related]
5. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
Fraterman I; Reijers ILM; Dimitriadis P; Broeks A; Gonzalez M; Menzies AMM; Lopez-Yurda M; Kapiteijn E; van der Veldt AAM; Suijkerbuijk KPM; Hospers GAP; Long GV; Blank CU; van de Poll-Franse LV
Nat Med; 2023 Dec; 29(12):3090-3099. PubMed ID: 37957378
[TBL] [Abstract][Full Text] [Related]
6. The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients - A Potential Paradigm Shift in Management.
Spillane AJ; Menzies AM; van Akkooi ACJ
Ann Surg Oncol; 2020 Jul; 27(7):2188-2200. PubMed ID: 32409966
[TBL] [Abstract][Full Text] [Related]
7. Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients.
Crookes TR; Scolyer RA; Lo S; Drummond M; Spillane AJ
Ann Surg Oncol; 2017 May; 24(5):1378-1385. PubMed ID: 28130620
[TBL] [Abstract][Full Text] [Related]
8. Clinical Prognostic Markers in Stage IIIB Melanoma.
Madu MF; Wouters MW; Klop WM; van der Hiel B; van de Wiel BA; Jóźwiak K; van der Hage JA; van Akkooi AC
Ann Surg Oncol; 2016 Dec; 23(13):4195-4202. PubMed ID: 27380642
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
Czarnecka AM; Ostaszewski K; Błoński PJ; Szumera-Ciećkiewicz A; Świtaj T; Kozak K; Koseła-Patreczyk H; Rogala P; Kalinowska I; Zaborowski K; Krotewicz M; Borkowska A; Rutkowski P
Cancer; 2024 Jun; ():. PubMed ID: 38843386
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
12. Not Waiting to Progress; How the COVID-19 Pandemic Nudged Neoadjuvant Therapy for Stage III Locally Advanced Melanoma Patients.
Kinaschuk K; Cheng T; Brenn T; McKinnon JG; Temple-Oberle C
Curr Oncol; 2023 Apr; 30(5):4402-4411. PubMed ID: 37232793
[No Abstract] [Full Text] [Related]
13. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
14. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
16. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract][Full Text] [Related]
17. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.
Lucas MW; Versluis JM; Rozeman EA; Blank CU
Nat Rev Clin Oncol; 2023 Jun; 20(6):408-422. PubMed ID: 37147419
[TBL] [Abstract][Full Text] [Related]
18. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
[TBL] [Abstract][Full Text] [Related]
19. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
Montagna E; Bagnardi V; Rotmensz N; Viale G; Pruneri G; Veronesi P; Cancello G; Balduzzi A; Dellapasqua S; Cardillo A; Luini A; Zurrida S; Gentilini O; Mastropasqua MG; Bottiglieri L; Iorfida M; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2010 Dec; 124(3):689-99. PubMed ID: 20625816
[TBL] [Abstract][Full Text] [Related]
20. Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era.
Hagopian G; Jiang X; Grant C; Brazel D; Kumar P; Yamamoto M; Jakowatz J; Chow W; Tran T; Shen W; Moyers J
ESMO Open; 2024 Feb; 9(2):102193. PubMed ID: 38271786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
